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357 
THE NEED FOR REGULATION OF DIRECT-TO-
CONSUMER GENETIC TESTING IN THE UNITED 
STATES: ASSESSING AND APPLYING THE 
GERMAN POLICY MODEL 
INTRODUCTION: OVERVIEW OF GENETIC TESTING 
In 2008, Time Magazine declared 23andMe’s1 retail DNA test the 
“Invention of the Year.”2 The actual value of this and other direct-to-
consumer (“DTC”) genetic tests remains to be seen, however, and 
government agencies worldwide have been left to decide if and how 
strictly to regulate this relatively new but growing field of genetic 
technology. 
The study of genetics began in earnest with Gregor Mendel’s principles 
of heredity in the 1860s.3 The importance of his work, however, was not 
recognized until 1900, when Hugo de Vries and two other researchers 
independently verified and published Mendel’s results.4 From there, 
scientists developed the chromosomal theory, and in 1953, Watson and 
Crick discovered the double helix structure of DNA as the chemical basis 
 
 
 1. See How it Works, 23ANDME, https://www.23andme.com/howitworks/ (last visited Nov. 9, 
2012) (“23andMe is a DNA analysis service providing information and tools for individuals to learn 
about and explore their DNA.”); see also Anita Hamilton, Best Inventions of 2008: The Retail DNA 
Test, TIME (Oct. 29, 2008), http://www.time.com/time/specials/packages/article/0,28804,1852747_ 
1854493_1854113,00.html (“The 600,000 genetic markers that 23andMe identifies and interprets for 
each customer are ‘the digital manifestation of you . . . .’”). Other prominent DTC testing companies 
include deCODE Genetics, Pathway Genomics, Map My Gene, and Gene Planet. See GPPC Releases 
Updated List of DTC Genetic Testing Companies, GENETICS & PUB. POLICY CTR. (Aug. 11, 2011) 
[hereinafter GPPC List], http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=145, 
http://www.dnapolicy.org/resources/DTCTableAug2011Alphabydisease.pdf. 
 2. Hamilton, supra note 1. 
We are at the beginning of a personal-genomics revolution that will transform not only how 
we take care of ourselves but also what we mean by personal information. [N]ow personal 
genotyping is available to anyone who orders the service online and mails in a spit sample. 
Not everything about how this information will be used is clear yet—23andMe has stirred up 
debate about issues ranging from how meaningful the results are to how to prevent genetic 
discrimination—but the curtain has been pulled back, and it can never be closed again. And 
so for pioneering retail genomics, 23andMe’s DNA-testing service is Time’s 2008 Invention 
of the Year. 
Id. 
 3. Mendel’s 1865 research revealed that “[e]ach parent contributes one factor of each trait 
shown in offspring,” that the “two members of each pair of factors segregate from each other during 
gamete formation,” that “males and females contribute equally” to their offspring’s traits, and that 
“[a]cquired traits are not inherited.” See M. Tevfik Dorak, Landmarks in the History of Genetics, 
DORAK.INFO, http://www.dorak.info/genetics/notes01.html (last updated May 7, 2009). 
 4. Id. 
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for gene heredity.5 Throughout the mid and late twentieth century, genetic 
researchers made substantial advances, beginning with newborn screening 
for phenylketonuria6 in the 1960s, which ultimately led to screening for 
numerous other genetic diseases in the 1970s and 1980s.7 In 1990, 
scientists began the Human Genome Project, an international effort to 
discover and study all human genes and make them accessible for further 
biological research.8 Scientists also strove to determine the complete 
sequence of the three billion DNA base pairs in the human genome.9 The 
project was completed in 2003, two years ahead of schedule.10 
As a result of these efforts, scientists have now developed genetic tests 
for more than 2,200 diseases; around 2,000 of those tests can be used 
today in clinical settings.11 However, since researchers have yet to 
pinpoint most of the genetic components that cause diseases, genetic 
testing may not provide a complete or totally valid result.12 Some genetic 
tests focus on a single gene or genetic mutation to detect a specific genetic 
disorder, but so-called genomic technologies13 have been developed to 
examine “multiple genes that may increase or decrease a person’s risk of 
 
 
 5. Id. 
 6. Phenylketonuria is a rare genetic error of metabolism that, if left untreated, leads to mental 
retardation and other health abnormalities. Treatment involves placing newborns on a special diet from 
which most of the phenylalanine has been removed. See Diane B. Paul, The History of 
Phenylketonuria Testing in the U.S., in FINAL REPORT OF THE TASK FORCE ON GENETIC TESTING A5 
(Neil A. Holtzman & Michael S. Watson eds., 1997), available at http://biotech.law.lsu.edu/research/ 
fed/tfgt/appendix5.htm. 
 7. See Ricki Lewis, A Brief History of Genetic Testing, SCIENCE PROGRESS (May 5, 2008), 
http://scienceprogress.org/2008/05/a-brief-history-of-genetic-testing/ (In the 1970s, scientists began 
newborn and population testing for Tay-Sachs disease and Sickle Cell disease. This was followed by 
advances in prenatal and carrier testing for diseases such as Down’s syndrome and cystic fibrosis). 
 8. See History of the Human Genome Project, OAK RIDGE NAT. LAB., http://www.ornl.gov/sci/ 
techresources/Human_Genome/project/hgp.shtml (last update June 4, 2012). 
 9. Id. 
 10. Press Release, Int’l Human Genome Sequencing Consortium, Int’l Consortium Completes 
Human Genome Project (Apr. 14, 2003), http://www.ornl.gov/sci/techresources/Human_Genome/pro 
ject/50yr/press4_2003.shtml. Other stated goals of the Human Genome Project were to store the 
genomic information in databases, “improve tools for data analysis, transfer related technologies to the 
private sector, and address the ethical, legal, and social issues (ELSI) that may arise from the project.” 
See About the Human Genome Project, OAK RIDGE NAT. LAB., http://www.ornl.gov/sci/techresources/ 
Human_Genome/project/about.shtml (last updated Sept. 19, 2011) (emphasis in original). 
 11. See Public Health Genomics: Genetic Testing, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/genomics/gtesting/ (last updated May 3, 2012). 
 12. Id. 
 13. See Public Health Genomics: Genomics and Health, CTRS. FOR DISEASE CONTROL AND 
PREVENTION, http://www.cdc.gov/genomics/public/index.htm (last updated Sept. 18, 2012) 
(“Genomic” hyperlink). Genomic testing refers to the study of a person’s entire genetic makeup, rather 
than gene-specific testing, and “the relationship between genes, environment, and behaviors” which 
can explain “why some people get sick, while others do not.” Id. 
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common diseases, such as cancer or diabetes.”14 These types of tests 
analyze an individual’s DNA for individual base15 changes called single 
nucleotide polymorphisms (“SNPs”)16 to then estimate the individual’s 
risk for certain conditions, both common and rare.17 Estimated risk 
predictions are based on studies comparing the existence of certain SNPs 
to the occurrence of certain conditions and diseases within a greater 
population.18 
Direct-to-consumer (“DTC”) marketing for genome-wide genetic tests 
emerged as the Human Genome Project came to an end.19 Companies 
began using print, television, and Internet advertising to reach 
consumers—a framework previously employed predominantly by 
pharmaceutical companies.20 More DTC testing companies emerged 
worldwide as internet access and usage increased throughout the next 
decade, allowing consumers to directly order test kits online without ever 
involving a physician or genetics specialist.21 Typically, consumers go to 
one of the DTC testing company websites, order the test kit,22 take either a 
saliva sample or cheek swab using the kit, send the kit back to the 
company, and receive their results within several weeks, usually via the 
 
 
 14. Id. 
 15. “The information in DNA is stored as a code made up of four chemical bases . . . .” (adenine, 
guanine, cytosine, and thymine). There are about three billion bases in human DNA. The sequence of 
these bases determines the information available for building and maintaining an organism (i.e. a 
person’s genetic code). See What is DNA?, GENETICS HOME REFERENCE, http://ghr.nlm.nih.gov/hand 
book/basics/dna (last updated May 13, 2013). 
 16. “Single nucleotide polymorphisms, frequently called SNPs . . . are the most common type of 
genetic variation. . . . Each SNP represents a difference in a single DNA building block [or base], 
called a nucleotide.” There are about ten million SNPs in the human genome, and most have no effect 
on a person’s health. What Are Single Nucleotide Polymorphisms (SNPs)?, GENETICS HOME 
REFERENCE, http://ghr.nlm.nih.gov/handbook/genomicresearch/snp (last updated May 13, 2013). 
However, some of these SNPs may help physicians and researchers “predict an individual’s response 
to certain drugs, susceptibility to certain environmental factors . . . and risk of developing particular 
diseases. SNPs can also be used to track the inheritance of disease genes within families.” Id. 
 17. See Karen Norrgard, DTC Genetic Testing for Diabetes, Breast Cancer, Heart Disease and 
Paternity, 1 NATURE EDUC. 1, 1 (2008), available at http://www.nature.com/scitable/topicpage/dtc-gen 
etic-testing-for-diabetes-breast-cancer-698. 
 18. Id.  
 19. See Direct to Consumer Marketing of Genetic Tests, NAT’L HUMAN GENOME RESEARCH 
INST. (Mar. 23, 2004), http://www.genome.gov/12010659. 
 20. Id. (“The advertising of health-related products directly to consumers, a $3 billion per year 
industry, first appeared in the early 1980’s with the marketing of prescription drugs in print and 
television advertisements.”). 
 21. Jane Kaye, The Regulation of Direct-to-Consumer Genetic Tests, 17 HUMAN MOLECULAR 
GENETICS R180 (2008), available at http://hmg.oxfordjournals.org/content/17/R2/R180.full.pdf+html. 
 22. Test kits typically include instructions on how to collect the DNA sample, a tube and/or swab 
to be used for saliva collection, and a pre-addressed package to send the sample to the DTC testing 
company. Consumer’s Guide to Genetic Testing, CTR. FOR JEWISH GENETICS (2008), http://www.jew 
ishgenetics.org/?q=content/consumer%E2%80%99s-guide-direct-consumer-genetic-testing.  
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internet.23 Depending on the amount of genetic information involved and 
whether or not the test kit purchased includes a genetic counseling 
component, DTC testing can cost as little as one hundred dollars.24 
According to a study conducted by the Genetics and Public Policy 
Center, there were twenty DTC testing companies in the United States and 
seven additional DTC companies that required physicians to request the 
DNA tests as of August 2011.25 Of the twenty DTC testing companies, 
eight offer some sort of genetic counseling to consumers, though only five 
do so without additional costs.26 Each company tests for predispositions to 
various diseases and characteristics, differing widely depending on the 
company. They test for genetic conditions ranging from serious, 
untreatable diseases such as Alzheimer’s disease and Lou Gehrig’s disease 
(“ALS”) to physical characteristics, such as male pattern baldness, and 
personality traits.27 
This Note explores the ever-evolving genetics testing industry, 
specifically DTC tests that are manufactured and marketed by private 
companies.28 Part I evaluates the arguments in favor of DTC genetic 
testing, and Part II assesses the concerns held by those opposed to DTC 
testing. After giving an overview of the current United States regulatory 
framework in Part III, Part IV outlines a selection of regulatory 
 
 
 23. Pauline C. Ng et al., An Agenda for Personalized Medicine, 461 NATURE 724, 724 (Oct. 8, 
2009), available at http://www.gis.a-star.edu.sg/internet/site/data/sup_data/2249/an_agenda_for_perso 
nalized_medicine.pdf. 
 24. See, e.g., Store, 23ANDME, https://www.23andme.com/store/cart (last visited Jan. 20, 2012) 
(a single $99 test, plus $9.95 shipping). 
 25. GENETICS & PUB. POL’Y CTR., supra note 1. Excluded from the study were companies “not 
offering testing for at least one medical condition, one pharmacogenomic test, or one nutrigenomic 
test,” meaning “companies that sell only fetal sex tests, ancestry tests, and/or paternity/identity tests.” 
Id.  
 26. Id. For example, additional costs associated with obtaining genetic counseling via 23andMe 
can go up to $375. See Comprehensive Clinical Genetic Counseling Session, INFORMED MED. 
DECISIONS, http://informeddna.com/index.php/23andme.html (last visited Nov. 9, 2012). 
 27. See GPPC List, supra note 1. 
 28. This Note will focus on these predictive genome-wide DTC genetic tests rather than 
pharmacogenetic/pharmacogenomic testing. Pharmacogenomic testing is a growing field that 
examines the small inherited variations in patients’ genes’ nucleotide content that dictate drug 
response and “explores the ways these variations can be used to predict” how a patient will respond or 
not respond to a certain drug. See One Size does not Fit All: The Promise of Pharmacogenomics, 
NAT’L CTR. FOR BIOTECHNOLOGY INFO. (Mar. 31, 2004), http://www.ncbi.nlm.nih.gov/About/primer/ 
pharm.html. This Note will not discuss nutrigenomic testing, which involves genome-wide genetic 
testing in combination with lifestyle factors, such as diet, exercise, and smoking, of the tested 
individual to assess his or her potential health risks. Companies offering these tests then present 
recommendations, often including nutritional supplements sold by the testing company. See Katrina 
A.B. Goddard et al., Awareness and Use of Direct-to-Consumer Nutrigenomic Tests, United States, 
2006, 9 GENETICS IN MED. 510, 510 (Aug. 2007), available at http://www.cdc.gov/genomics/update/ 
file/print/goddard_dtc.pdf. 
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recommendations published by various American and international 
genetics organizations and governmental agencies. Part V then examines 
Germany’s regulatory approach, which results in an effective ban on DTC 
genetic testing. Ultimately, after addressing some proposed solutions, Part 
VI advocates for a regulatory approach in the United States comparable to 
Germany’s, though less strict and more nuanced. 
I. POTENTIAL BENEFITS OF DIRECT-TO-CONSUMER GENETIC TESTING 
Proponents of DTC testing, including scholars and the DTC companies 
themselves, cite numerous benefits that could result from genetic testing. 
These DTC testing services make genetic testing more accessible, because 
they are relatively affordable and not dependent on an individual’s 
geographic location or ability to meet with a physician or geneticist.29 
Moreover, DTC testing companies and some scholars highlight the 
benefits of individual autonomy and the right of individuals to access their 
own personal genetic information—part of their identity—without the 
involvement of a physician.30 Proponents believe this autonomy leads to 
greater consumer empowerment because it allows individuals to make 
proactive, preventive lifestyle changes in response to test results indicating 
predispositions to various conditions.31 Such a development, in theory, 
should ultimately lead to improved overall health in those consumers.32 
This “personalized medicine” approach, according to proponents of 
DTC testing, gives individuals the ability to make more informed medical 
decisions, focusing on prevention, prediction, and targeted intervention 
earlier than was possible before genomic testing.33 If an individual’s 
results indicate a significantly higher risk for a certain disease or 
condition, he or she may begin screening for that disease early in order to 
 
 
 29. See Norrgard, supra note 17, at 1–2; see also CTR. FOR JEWISH GENETICS, supra note 22.  
 30. Policy Forum, 23ANDME, https://www.23andme.com/about/policy/ (last visited Oct. 1, 2012) 
(“Genetic information is a fundamental element of a person’s body, identity and individuality. As 
such, the rights that people enjoy with regard to financial, medical and other forms of personal 
information should apply to genetic information as well.”); see also ROBERT W. KOLB, THE ETHICS OF 
GENETIC COMMERCE 58–60 (2007) (the policy presupposition favoring individual autonomy—the 
right to be free to make self-regarding decisions without coercion or manipulation—favors allowing 
people to choose to access their own genetic information via DTC testing). 
 31. Norrgard, supra note 17, at 4. 
 32. Id. 
 33. Personalized Medicine, U.S. NEWS & WORLD REPORT, http://health.usnews.com/health-con 
ditions/cancer/personalized-medicine#2 (last updated Jan. 1, 2011) (“Personalized medicine is about 
making the treatment as individualized as the disease. It involves identifying genetic, genomic, and 
clinical information that allows accurate predictions to be made about a person’s susceptibility of 
developing disease, the course of disease, and its response to treatment.”). 
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detect the disease and prevent it from progressing significantly.34 There is 
no clear indication, however, that individuals actually change their 
lifestyle or behavior once they receive the genetic predisposition results.35 
Proponents also emphasize increased privacy as a major benefit of 
DTC testing. Without the involvement of a physician, test results do not 
become part of an individual’s medical records, which can leave them 
vulnerable to discrimination by employers or insurers based on their 
genetic predispositions.36 This was more of a concern before the 2008 
passage of the Genetic Information Nondiscrimination Act (“GINA”),37 
but DTC testing companies still emphasize complete security, privacy, and 
individual control over access to the genetic information.38 Proponents 
note, however, that should an individual choose to share his or her DTC 
testing results, the educational value of such genetic information could be 
highly beneficial to family members and would increase public awareness 
of genetic diseases in general.39 DTC testing might also challenge health 
care providers to become better educated about genetics and heritability.40 
Finally, DTC testing proponents argue that there is public enthusiasm for 
genetic testing and information, and testing companies provide for this 
unmet need.41 
 
 
 34. See id.  
 35. See Bridget M. Kuehn, Risks and Benefits of Direct-to-Consumer Genetic Testing Remain 
Unclear, 300 J. AM. MED. ASS’N 1503, 1503–04 (2008), available at http://web.mit.edu/writing/2009/ 
June/Risks_and_Benefits_of_Direct_Genetic_Testing.pdf. Thus, further study of the behavior of those 
who undergo predictive genetic testing would be useful to evaluate the purported merits of DTC 
testing and personalized medicine. 
 36. See Norrgard, supra note 17, at 1–2; Adam J. Wolfberg, Genes on the Web—Direct-to-
Consumer Marketing of Genetic Testing, 355 NEW ENG. J. MED. 543, 543 (2006); Policy Forum, 
23ANDME, supra note 30. 
 37. The Genetic Information Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110-233, 122 
Stat. 881 (2008), prohibits health insurers from requesting or requiring genetic information of an 
individual or the individual’s family members or from using the genetic information for decisions 
regarding coverage, rates, or preexisting conditions. The law also prohibits most employers from using 
genetic information to make employment decisions. It provides a basis for state nondiscrimination 
laws. However, GINA does not apply to life insurance, disability insurance, or long-term care 
insurance. See Information for Researchers and Health Care Professionals, DEP’T OF HEALTH AND 
HUMAN SERVS. (Apr. 6, 2009), http://www.genome.gov/Pages/PolicyEthics/GeneticDiscrimination/GI 
NAInfoDoc.pdf. 
 38. See, e.g., Policy Forum, 23ANDME, supra note 30. 
 39. Id.; see also CTR. FOR JEWISH GENETICS, supra note 22. 
 40. See Norrgard, supra note 17, at 4. 
 41. See Stuart Hogarth et al., The Current Landscape for Direct-to-Consumer Genetic Testing: 
Legal, Ethical, and Policy Issues, 9 ANN. REV. OF HUMAN GENETICS 161, 168 (2008), available at 
http://step.berkeley.edu/Journal_Club/paper1_04212009.pdf (“[T]here is a public appetite for 
information about the fruits of the Human Genome Project, and that lack of clinical uptake of new 
tests can be addressed by DTC advertising and test provision.”). 
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II. POSSIBLE DRAWBACKS OF DIRECT-TO-CONSUMER GENETIC TESTING 
Despite these asserted benefits, many scientists and scholars harbor 
serious concerns about the clinical validity,42 analytical validity,43 and 
clinical utility44 of predictive DTC testing. In addition, some in the 
genetics field fear that DTC testing may result in negative psychological 
and social consequences and problematic ethical issues related to informed 
consent. These concerns underlie the numerous cautionary public policy 
recommendations outlined in Part IV of this Note. 
A. Clinical and Analytical Validity Concerns 
Though most scholars agree that the raw data obtained via DTC genetic 
testing is accurate, some are concerned about the clinical validity of such 
tests.45 Genetic testing is generally more susceptible to laboratory 
problems than other types of testing, including less laboratory vigilance, 
since most genetic testing results do not indicate abnormalities.46 DTC 
companies handle a high volume of tests and often contract the actual 
genetic testing out to a third party company, which increases the risk of 
mix-ups between tests.47 In fact, in June 2010, 23andMe announced that 
up to ninety-six individuals may have received and viewed results that 
were not their own, due to human error in the processing of their saliva 
samples by the laboratory 23andMe employed to conduct their tests.48 
 
 
 42. Id. at 169. Clinical validity means that the test result correlates with the presence or absence, 
or heightened risk of a specific disease. 
 43. Id. Analytical validity means that the test consistently and correctly shows that a specific 
gene mutation is present or absent. 
 44. See Audrey Huang, Who Regulates Genetic Tests?, GENETICS & PUB. POL’Y CTR., http:// 
www.dnapolicy.org/images/issuebriefpdfs/Who_Regulates_Genetic_Tests_Issue_Brief.pdf (last updated 
May 30, 2008) (“Clinical utility refers to whether using the test has a positive impact on a patient’s 
health and wellbeing.”). 
 45. See, e.g., Ng et al., supra note 23. 
 46. See LORI B. ANDREWS ET AL., ASSESSING GENETIC RISKS: IMPLICATIONS FOR HEALTH AND 
SOCIAL POLICY 116–17, 127 (1994), available at http://www.nap.edu/catalog.php?record_id=2057. 
 47. See Jennifer A. Gniady, Note, Regulating Direct-to-Consumer Genetic Testing: Protecting 
the Consumer Without Quashing a Medical Revolution, 76 FORDHAM L. REV. 2429, 2447 (2008), 
available at http://ir.lawnet.fordham.edu/cgi/viewcontent.cgi?article=4354&context=flr. 
 48. Turna Ray, UPDATE: 23andMe Says LabCorp Incorrectly Processed 96 Samples, Mixing up 
Customer Data, PHARMACOGENOMICS REPORTER (June 9, 2010), http://www.genomeweb.com/dxpgx/ 
23andme-says-labcorp-incorrectly-processed-96-samples-mixing-customer-data. 
23andMe said it is considering implementing various safeguards to ensure this type of error 
does not happen again, including removing manual steps at the lab, completely automating 
the sample analyses, and implementing further data checks before uploading it to customer 
accounts. . . . Additionally, 23andMe said it will collect data regarding sex for all new 
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Moreover, there are often disparities in results between different 
genetic testing companies.49 This occurs, at least in part, because 
companies use different population definitions when determining the 
average population disease risk50 and different sets of clinically validated 
genetic markers in calculating relative disease risk.51 For example, one 
small study comparing 23andMe and Navigenics DTC test results found 
that only two-thirds of relative risk predictions between the two companies 
qualitatively matched.52 Similarly, for seven diseases, fifty percent or less 
of the predictions of the two companies agreed.53 Finally, since the 
markers discovered and used by DTC testing companies do not explain the 
majority of the genetic heritability of disease, the test results can be 
inherently misleading.54 If two different DTC testing companies present 
the consumer with inconsistent results, the consumer may be left 
wondering which results to believe. 
B. Clinical Utility Concerns 
Since genomic test results, for most people, do not reveal a 
significantly increased risk for many genetic diseases, physicians or 
patients do not usually have a clear course of action to take.55 This results 
 
 
customers prior to laboratory processing as an additional quality check ahead of uploading 
data. 
Id. 
 49. See Ng et al., supra note 23, at 724. 
 50. Id. For example, some DTC companies distinguish between men and women when 
determining average population disease risk, while others distinguish populations primarily based on 
age. Because of these definitional differences, consumers could receive disparate results when their 
risk is compared to that of the greater population. 
 51. Id. 
Risk markers are determined from genome-wide association studies. . . . Each marker has 
different possible alleles. Alleles that occur more frequently in disease patients are designated 
as risk alleles and have odds ratios greater than 1. . . . DTC companies harness the same 
publicly available research to decide which markers to include, and for the most part, could 
use the same or similar markers. Yet no disease has an identical set of markers between the 
two DTC companies because each company has its own criteria for accepting a genome-wide 
association result into its relative risk calculation. 
Id. 
 52. Id. 
 53. Id. 
 54. See id. at 725; see also CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 11 
(“Despite the many scientific advances in genetics, researchers have only identified a small fraction of 
the genetic component of most diseases. Therefore, genetic tests for many diseases are developed on 
the basis of limited scientific information and may not yet provide valid or useful results to individuals 
who are tested.”). 
 55. See Kuehn, supra note 35, at 1505. 
https://openscholarship.wustl.edu/law_globalstudies/vol12/iss2/9
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in limited clinical utility for most DTC test results.56 Clinical utility is 
further limited because most tests do not mandate sufficient genetic 
counseling.57 Consumers might be confused or have difficulty 
understanding the often-nuanced results.58 If the individual does not 
interpret his or her results correctly, he or she cannot take the appropriate 
preventive measures and may even make adverse medical decisions.59 For 
example, an individual may undergo unnecessary preventive testing or 
unnecessary procedures such as a prophylactic mastectomy in response to 
a genetic test showing an increased risk of breast cancer.60 They might also 
cease using prescribed medications.61 These unnecessary procedures and 
tests could drain the health care system, using physicians’ time and health 
care funds that would otherwise be used for proven and necessary medical 
reasons.62 
C. Psychological Consequences 
Due to the lack of thorough, face-to-face genetic counseling, there are 
concerns about the possible negative psychological effects of DTC testing 
results. Though not empirically proven, many scholars and practitioners 
have discussed psychological and social consequences such as 
reinforcement of deterministic attitudes, serious self-identity difficulties, 
strained familial relationships, and increased anxiety and depression.63 
Since many DTC test consumers will not receive meaningful genetic 
 
 
 56. Id. at 1504–05. 
 57. Even those DTC companies that do offer or require some form of genetic counseling usually 
only provide “telephone or on-line counseling,” which at least some scholars and many clinicians 
believe to be an unsatisfactory substitute. Sivan Tamir, Direct-to-Consumer Genetic Testing: Ethical-
Legal Perspectives and Practical Considerations, 18 MED. L. REV. 213, 219 (2010); see also Adam J. 
Wolfberg, supra note 36, at 544. 
 58. See Hogarth et al., supra note 41, at 168 (using the example of BRCA genes to show the 
importance of understanding the nuances and context of test results). 
 59. Tamir, supra note 57, at 219. 
 60. Id. 
 61. Id. 
 62. Amy L. McGuire & Wiley Burke, An Unwelcome Side Effect of Direct-to-Consumer 
Personal Genome Testing, 300 J. AM. MED. ASS’N. 2669, 2669 (2008) (highlighting the need to 
protect the “medical commons” and resolve the clinical utility problems of DTC genomic testing).  
 63. See Gabrielle Kohlmeier, The Risky Business of Lifestyle Genetic Testing: Protecting Against 
Harmful Disclosure of Genetic Information, 2007 UCLA J.L. & TECH. 5, 24 (2007), available at 
http://www.lawtechjournal.com/articles/2007/05_071230_kohlmeier.pdf. These negative psychosocial 
effects are especially applicable when DTC testing shows near certain probability of an untreatable 
genetic disease, such as Huntington’s disease or Familial Adenomatous Polyposis (inherited colorectal 
cancer where existence of the gene translates into a nearly one hundred percent chance of developing 
colon polyps and colorectal cancer). See Diseases & Conditions—FAP, CLEVELAND CLINIC, 
http://www.clevelandclinic.org/registries/inherited/fap.htm (last visited Sept. 25, 2012). 
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counseling and, consequently, may misinterpret their DTC test results, 
these psychological reactions may be founded upon a faulty understanding 
of these test results.64 Moreover, misinterpretation of DTC test results may 
lead to a false sense of security if results show a lower probability of 
disease than anticipated.65 
D. Ethical Problems 
The possibilities of non-consent or a lack of informed consent worry 
many medical and genetics professionals. DTC testing companies have no 
definitive way of knowing if the individual requesting the test sends in his 
or her own DNA sample.66 In other words, an individual could collect the 
genetic material of another person without that person’s consent and 
subsequently obtain and use the genetic information received from the 
DTC testing company.67 This could amount to a violation of human 
dignity and a serious breach of privacy.68 
Even when an individual consents to DTC genetic testing, this consent 
might not be informed, completely autonomous consent.69 Misleading 
advertising by DTC testing companies minimizes the risks and overstates 
the possible benefits of genomic testing.70 The advertisements may 
“induce vulnerable consumers to purchase the tests, thereby diminishing 
their autonomy.”71 The advertisements also tend to delude consumers into 
thinking that their genetic traits alone determine their risk of developing a 
 
 
 64. See Hogarth et al., supra note 41, at 168. Test results can be nuanced and complex, leading to 
misinterpretation and mistaken belief that one has an increased genetic risk of developing certain 
diseases. 
 65. See Norrgard, supra note 17, at 3 (discussing the possible false sense of security if a woman 
tests negative for genetic mutations causing breast and ovarian cancer, BRCA 1 and 2). Absence of 
those genetic mutations alone does not preclude the possibility that a woman will develop such 
cancers, which can be caused by a myriad of factors. This false sense of security might ultimately be 
detrimental if a woman forgoes screening and preventative measures as a result. Id. 
 66. Tamir, supra note 57, at 221. 
 67. Id. 
Non-consensual use of genetic testing pertains to unlawful actions, where genetic material 
(i.e. saliva left on a glass, hair follicles, etc.) is obtained, through collection or removal, 
without the consent of the (involuntary) ‘source’ and consequently, the genetic information 
derived is used, without the source’s consent, to his or her detriment, or to benefit others.  
Id. The article provides three examples of situations when non-consensual genetic testing might occur.  
 68. Id. at 222 (“[A]n intrusion on basic human dignity and autonomy, a violation of the source’s 
bodily integrity, a breach of information privacy, and essentially deprives the source of the opportunity 
to exercise his right not to know particular genetic information.”). 
 69. See Deepthy Kishore, Test at Your Own Risk: Your Genetic Report Card and the Direct-to-
Consumer Duty to Secure Informed Consent, 59 EMORY L.J. 1553, 1576, 1590–93 (2010). 
 70. Id. at 1590, 1592–93. 
 71. Id. 
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disease when heredity is actually only one factor.72 In 2006, as a result of 
this misleading advertising, the Federal Trade Commission (“FTC”) issued 
a consumer fact sheet detailing suggested guidelines for individuals 
considering DTC genetic testing.73 Ultimately, the FTC urged consumer 
caution.74 
III. THE UNITED STATES REGULATORY FRAMEWORK 
Despite the disagreement and risks associated with DTC genetic 
testing, the United States federal government exerts only minimal control 
over genetic testing laboratories and the DTC testing industry.75 Currently, 
federal regulatory authority over DTC testing falls within the province of 
the Food and Drug Administration (“FDA”), the Centers for Medicaid and 
Medicare Services (“CMS”) under the Clinical Laboratory Improvement 
Amendments of 1988 (“CLIA”), state governments and agencies, and the 
FTC.76 None of the regulatory bodies, however, have clear authority over 
the accuracy, design, and application of DTC genetic tests.77 
Currently, the FDA regulates in vitro diagnostic devices (“IVDDs”)78 
as medical devices, via the Medical Device Amendment of the Federal 
Food, Drug, and Cosmetic Act (“FDCA”).79 However, the vast majority of 
 
 
 72. Id. at 1593 (“One study showed that 95% of websites for DTC genetic testing services lacked 
information about the significance of lifestyle, family history, or routine screening.”). 
 73. Facts for Consumers—At-Home Genetic Tests: A Healthy Dose of Skepticism May Be the 
Best Prescription, U.S. FED. TRADE COMM’N (FTC) (July 2006), http://www.ftc.gov/bcp/edu/pubs/ 
consumer/health/hea02.shtm. 
 74. Id. Recommendations for consumers include pre-test consultation with their physician and/or 
genetic counselor and post-test discussion of the results to aid in interpretation and next steps or 
prevention. The FTC also warns consumers that DTC tests are not subject to FDA approval. Id. 
 75. Hogarth et al., supra note 41, at 170. 
 76. See Andrew S. Robertson, Note, Taking Responsibility: Regulations and Protections in 
Direct-to-Consumer Genetic Testing, 24 BERKELEY TECH. L.J. 213, 221 (2009), available at http:// 
www.btlj.org/data/review/24-213-243.pdf; see also Gniady, supra note 47, at 2452–53 (discussion of 
the FTC’s somewhat limited regulatory authority, which extends only to prohibiting false or 
misleading advertising related to DTC genetic testing).  
 77. Robertson, supra note 76, at 221. 
 78. Genetic tests are IVDDs (“test kits”) if the components are bundled, labeled, and sold to a 
laboratory as a unit. IVDs must undergo premarket review of safety, accuracy, and utility before they 
may be distributed commercially. Audrey Huang, FDA Regulation of Genetic Tests, GENETICS & PUB. 
POL’Y CTR., http://www.dnapolicy.org/policy.issue.php?action=detail&issuebrief_id=11 (last updated 
May 30, 2008). 
 79. Id. Congress passed the Federal Food, Drug, and Cosmetic Act in 1938 “after a legally 
marketed toxic elixir killed 107 people . . . .” Regulatory Information: Legislation, U.S. FOOD & DRUG 
ADMIN. (FDA), http://www.fda.gov/RegulatoryInformation/Legislation/default.htm (last updated July 
9, 2012). The legislation “overhauled the public health system and authorized the FDA to [require 
proof] of safety for new drugs, issue standards for food, and conduct factory inspections.” Id. The 
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DTC genetic tests are not IVDDs or “test kits,” but rather laboratory 
developed tests (“LDTs”).80 In fact, “test kits” subject to FDA review 
make up only about one percent of the commercially available genetic 
tests.81 The only exceptions are in vitro diagnostic multivariate index 
assays (“IVDMIAs”), which use laboratory data and an algorithm to 
generate a result with the purpose of diagnosing, treating, or preventing 
diseases such as breast cancer, prostate cancer recurrence, and 
cardiovascular disease.82 Thus, because the FDA exercises its enforcement 
discretion,83 LDTs and DTC tests exist in a loophole, and most are not 
subject to any analysis to gauge their clinical validity before marketing 
and use.84 
LDTs and DTC testing do fall under CMS’s power to implement and 
enforce the CLIA, which “applies to all clinical laboratories that operate or 
provide testing services in the United States.”85 Genetic testing is not, 
however, subject to proficiency testing requirements for high-complexity 
laboratory tests.86 This has led to some concern among genetics scholars 
and professionals about the lack of CLIA oversight over genetic testing 
and a lack of transparency in the enforcement process.87 To address these 
concerns, many have called for laboratory guidelines specifically tailored 
to genetic testing.88 
 
 
Medical Device Amendments of 1976 applied effectiveness standards and safety precautions to newer 
devices. Id. 
 80. See Robertson, supra note 76, at 221. LDTs are “genetic tests that are designed and produced 
within a clinical laboratory . . . .” 
 81. See Gniady, supra note 47, at 2438 (citing Huang, supra note 44). 
 82. These types of tests, according to draft guidelines, are considered medical devices and are 
subject to FDA premarket review. See FDA, DRAFT GUIDANCE FOR INDUSTRY, CLINICAL 
LABORATORIES, AND FDA STAFF: IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS (July 26, 
2007), available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guid 
anceDocuments/ucm071455.pdf. 
 83. The FDA may exercise discretion when deciding whether or not to promulgate and enforce 
certain non-legislative rules and regulations, and they may enforce them in the manner they see fit. 
These rules are interpretative. See 5 U.S.C. § 553(b)(A)(2006). 
 84. Robertson, supra note 76, at 224. 
 85. See Hogarth et al., supra note 41, at 170. 
 86. Id. 
CMS issued final regulations that implemented CLIA in 1992. These regulations created 
“specialty areas” for laboratories that perform high-complexity tests, which specified 
personnel, quality assurance, and proficiency testing requirements for tests such as toxicology 
and immunology. Genetic testing, which was in its infancy at the time, was not included in 
these specialty areas. As a result, proficiency testing was never mandated for genetic testing 
laboratories. 
Id. (internal citation omitted). 
 87. Id. 
 88. Id. 
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The FTC, another federal regulatory body, has the power to enforce a 
prohibition of misleading or deceptive advertising for DTC genetic tests.89 
In combination with the FDA, the FTC could ensure that consumers have 
correct information about claims made by DTC testing companies and 
manufacturers who do not have FDA approval for their products.90 The 
FTC could also enforce a mandatory disclaimer stating that the tests are 
not FDA approved or subject to FDA approval.91 
Finally, many states have exercised their authority to regulate DTC 
testing via laboratory regulations that are more stringent than CLIA 
requirements.92 Others have exercised authority to regulate who may order 
genetic tests and receive the results from the testing laboratories.93 In fact, 
as of 2007, thirteen states specifically prohibited DTC genetic testing.94 
Other states significantly limit the DTC testing industry by requiring 
physician referral or specifying that only certain tests are permissible for 
DTC marketing and sale.95 Meanwhile, twenty-five states and the District 
of Columbia remain silent on the issue and allow DTC testing without 
restrictions.96 
 
 
 89. See Gniady, supra note 47, at 2452. However, “the extent of the FTC’s regulatory authority 
extends only to prohibiting false or misleading advertising.” Id. 
 90. Id. at 2453. 
 91. Id. at 2472. 
 92. See Robertson, supra note 76, at 224 (citing Gail H. Javitt et al., Direct-to-Consumer Genetic 
Tests, Government Oversight, and the First Amendment: What the Government Can (and Can’t) Do to 
Protect the Public’s Health, 57 OKLA. L. REV. 251, 274 (2004)). Both New York and Washington 
have opted out of the CLIA program in favor of state-supervised alternatives, which are more stringent 
than CLIA. Id. 
 93. Id. 
 94. Id.; see also Aruna Prabhala, Center Releases Analysis of State DTC Laws, GENETICS & PUB. 
POL’Y CTR. (July 2007), http://www.dnapolicy.org/news.enews.article.nocategory.php?action=de 
tail&newsletter_id=24&article_id=100; GENETICS & PUB. POL’Y CTR., SURVEY OF DIRECT-TO-
CONSUMER STATUTES AND REGULATIONS (June 2007) [hereinafter GENETICS & PUB. POL’Y CTR., 
SURVEY], http://www.dnapolicy.org/resources/DTCStateLawChart.pdf. States that completely prohibit 
DTC testing without physician involvement are Alabama, Connecticut, Georgia, Hawaii, Idaho, 
Kentucky, Michigan, New Hampshire, Pennsylvania, Rhode Island, South Carolina, Tennessee, and 
Wyoming. GENETICS & PUB. POL’Y CTR., SURVEY, supra. 
 95. GENETICS & PUB. POL’Y CTR., SURVEY, supra note 94. For example, California allows DTC 
tests, but only those which test for “pregnancy, glucose level, cholesterol, occult blood, and any other 
test for which there is a test for a particular analyte approved by the federal Food and Drug 
Administration for sale to the public without a prescription in the form of an over-the-counter test kit.” 
Id. at 1. Essentially, this constitutes a de facto ban on DTC genetic testing. Similarly, New York 
effectively bans DTC testing via its provision stating that “[t]est results cannot be sent directly to 
patients except with written consent of the physician or authorized person . . . .” Id. at 9. 
 96. See id. 
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IV. RECOMMENDATIONS FROM U.S. AND EUROPEAN GOVERNMENTAL, 
MEDICAL, AND GENETICS ORGANIZATIONS 
The U.S. Government Accountability Office (“GAO”), the FDA, and 
several domestic and European medical and genetics professional 
organizations have issued recommendations regarding DTC testing. 
Despite these recommendations, U.S. government regulation remains lax. 
In 2010, the GAO published testimony before the Subcommittee on 
Oversight and Investigations of the House Energy and Commerce 
Committee, highlighting the deceptive DTC testing advertising claims.97 
The GAO conducted an analysis of several DTC testing companies’ 
results and asserted that the test results were misleading and had limited 
utility for consumers.98 
The FDA’s summary from its March 2011 Molecular and Clinical 
Genetics Panel Meeting also includes several recommendations related to 
DTC testing.99 The recommendations include only permitting pre-
symptomatic tests with high predictors for a disease100 and allowing 
pharmacogenetic DTC tests through either a prescription or a health care 
professional.101 The FDA also suggested that DTC testing companies 
employ a “knowledge test prior to providing the DTC clinical genetic test 
to assess whether the consumer understands the meaning and 
 
 
 97. U.S. GOV’T ACCOUNTABILITY OFFICE, DIRECT-TO-CONSUMER GENETIC TESTS: MISLEADING 
TEST RESULTS ARE FURTHER COMPLICATED BY DECEPTIVE MARKETING AND OTHER QUESTIONABLE 
PRACTICES, GAO-10-847T (July 22, 2010), available at http://www.gao.gov/new.items/d10847t.pdf. 
The GAO undertook this study in response to the Time article and the increasing availability and 
visibility of DTC testing. They 
[p]urchased 10 tests each from four companies, for $299 to $999 per test. GAO then selected 
five donors and sent two DNA samples from each donor to each company: one using factual 
information about the donor and one using fictitious information, such as incorrect age and 
race or ethnicity. After comparing risk predictions that the donors received for 15 diseases, 
GAO made undercover calls to the companies seeking health advice . . . To assess whether 
the tests provided any medically useful information, GAO consulted with genetics experts. 
GAO also interviewed representatives from each company. To investigate advertising 
methods, GAO made undercover contact with 15 DTC companies, including the 4 tested, and 
asked about supplement sales, test reliability, and privacy policies. GAO again consulted with 
experts about the veracity of the claims. 
Id. 
 98. Id. at 4. 
 99. See FDA, SUMMARY FROM THE MOLECULAR AND CLINICAL GENETICS PANEL MEETING—
MARCH 8 AND 9, 2011 (2011) [hereinafter FDA, SUMMARY], available at http://www.fda.gov/down 
loads/AdvisoryCommittees/CommitteesMeetinCommittees/MedicalDevices/MedicalDevicesAdvisory
Committee/MolecuMolecularandClinicalGenetic/UCM246907.pdf. 
 100. Some examples include Huntington’s disease and Adenomatous Polyposis. See CLEVELAND 
CLINIC, supra note 63; Kohlmeier, supra note 63. 
 101. See FDA, SUMMARY, supra note 99. 
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consequences of test results.”102 Finally, the FDA discussed requiring 
consumers to participate in qualified, professional genetic counseling with 
the purchase of a DTC genetic test.103 
Various medical and genetics organizations have issued policy 
statements and recommendations regarding DTC testing.104 
The Board of Directors of the American College of Medicine Genetics 
recommends that genetic testing should only be provided to the public 
through health care professionals, who should order the tests, interpret the 
results, and provide pre- and post-test genetic counseling to the 
individual.105 In addition, the American Society of Human Genetics 
(“ASHG”) recommends increased transparency and information 
accessibility in order to allow consumers to make informed decisions 
about DTC genetic testing.106 ASHG also calls for more education for 
health care providers about the risks and benefits of DTC testing,107 
laboratory regulations specifically targeting DTC genetic testing,108 and 
cooperation between the FDA, FTC, and CMS/CLIA to increase overall 
regulation of DTC testing.109 
 
 
 102. Id. This addresses the aforementioned ethical concerns about lack of informed consent 
among those who obtain DTC testing. 
 103. Id.  
 104. Policy statements are not binding upon consumers, DTC companies, or genetics 
professionals. They are professional guidelines and suggestions for professionals and policymakers to 
take into consideration. See, e.g., Letter from Eleanor D. Kinney, Section Chair, American Bar Ass’n 
Section on Admin. Law and Regulatory Practice, to Lisa Jones, Office of Mgmt. and Budget 3 (Dec. 
15, 2005), http://www.whitehouse.gov/sites/default/files/omb/assets/inforeg_good_guidance/c-aba.pdf 
(“[s]ince policy statements are not legally binding”); Admin. Conference of the U.S., 
Recommendation 92-2, at 2–3 (June 18, 1992), http://www.acus.gov/best-practices/wp-content/uploa 
ds/2011/09/92-2.pdf. 
 105. See AM. COLL. OF MED. GENETICS BD. OF DIRS. (ACMG), ACMG Statement on Direct-to 
Consumer Genetic Testing, 6 GENETICS MED. 60 (2004), available at http://www.acmg.net/Static 
Content/StaticPages/Direct_Consumer.pdf. 
 106. See AM. SOC’Y OF HUMAN GENETICS (ASHG), ASHG Statement on Direct-to-Consumer 
Genetic Testing in the United States, 81 AM. J. HUMAN GENETICS 635, 636 (2007), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950839/ (“To promote transparency and to permit 
providers and consumers to make informed decisions about DTC genetic testing, companies must 
provide all relevant information about offered tests in a readily accessible and understandable 
manner.”). 
 107. Id. at 636–37. 
To ensure that providers are aware that genetic tests are being provided DTC and that some of 
these tests may lack analytic or clinical validity, professional organizations should educate 
their members regarding the types of genetic tests offered DTC, so that providers can counsel 
their patients about the potential value and limitations of DTC testing. 
Id. 
 108. Id. at 637 (“To ensure the analytic and clinical validity of genetic tests offered DTC and to 
ensure that claims made about these tests are truthful and not misleading, the relevant agencies of the 
federal government should take appropriate and targeted regulatory action.”). 
 109. Id. ASHG also calls for a CDC study of “the impact of DTC testing on consumers . . . .” Id. 
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European genetics organizations have also issued policy statements. In 
2010, for example, the United Kingdom’s Human Genetics Commission 
(“HGC”) issued a framework of principles regarding DTC testing.110 
These principles include accurate, transparent advertising and provide 
information for consumers in an understandable and accessible way.111 
The HGC also recommended pre- and post-test counseling conducted by a 
qualified genetic counselor, standardized testing methodologies and 
regulated laboratory processes, and reasonable efforts to ensure actual 
consent.112 The Council of Europe issued an additional protocol to the 
Convention on Human Rights and Biomedicine, which stated, “[a] genetic 
test for health purposes may only be performed under individualised 
medical supervision.”113 The statement emphasized the need for genetic 
counseling before and after testing to ensure informed consent114 and 
clinical utility.115 These recommendations represent the views of many 
other similar medical and genetics organizations, as well as some 
European governments.116 
V. THE GERMAN APPROACH 
With the passage of the Human Genetic Examination Act, Gesetz über 
genetische Untersuchungen bei Menschen [Gendiagnostikgesetz] 
(“GenDG”), in 2009, the German government enacted many of these 
recommendations.117 The legislation requires genetic testing laboratory 
accreditation, fully informed consent, and genetic counseling for all 
genetic testing.118 Moreover, it makes anonymous paternity tests illegal,119 
 
 
 110. See HUMAN GENETICS COMM’N. (U.K.), A Common Framework of Principles for Direct-to-
Consumer Genetic Testing Services, BRIT. SOC. FOR HUMAN GENETICS (July 2010), http://www.sashg 
.org/documents/HGC-UK-Policy-on-DTC-testing.pdf. 
 111. Id. at 6–7. 
 112. Id. at 4, 7, 9–11. 
 113. Additional Protocol to the Convention on Human Rights and Biomedicine, Concerning 
Genetic Testing for Health Purposes art 7, ¶ 1 (2008), available at http://conventions.coe.int/treaty/en/ 
treaties/html/203.htm. 
 114. Id. arts. 9, 10. 
 115. Id. art. 6. 
 116. Countries with federal legislation regulating and limiting genetic testing and DTC testing 
include Austria, Belgium, France, Norway, the Netherlands, and Sweden. See Hogarth et al., supra 
note 41, at 172. 
 117. See Untersuchungen bei Menschen [Gendiagnostikgesetz—GenDG] [Human Genetic 
Examination Act], July 31, 2009, Bundesgesetzblatt [BGBI] at 2529 (Ger.) [hereinafter GenDG], 
available at http://www.eurogentest.org/uploads/1247230263295/GenDG_German_English.pdf 
(contains original German version and English translation).  
 118. Id. §§ 5, 13. 
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prohibits parents from using genetic testing to determine the sex of their 
unborn children,120 and prohibits genetic discrimination.121 The GenDG 
also establishes the independent Genetic Diagnostic Commission, which 
develops guidelines and reviews new developments in science and 
technology.122 Most importantly for the DTC testing industry, the 
legislation states that predictive genetic examinations may only be ordered 
through medical doctors that have specialized genetics training and that 
provide genetic counseling services.123 In other words, all potential 
providers of DTC genetic testing would need to persuade German 
regulatory authorities that their services provide educational and/or 
informational products rather than medical or clinical services.124 The 
provision, in essence, amounts to a complete ban of DTC genetic testing 
kits ordered directly by consumers.125 
The legislation’s stated purpose is “to protect human dignity and ensure 
the individual right to self-determination via sufficient information.”126 
According to the Deutsches Referenzzentrum für Ethik in den 
Biowissenschaften, the GenDG’s requirements for predictive genetic 
testing are based on the individual right to “informational self-
determination”127 and concerns about genetic discrimination for insurance 
 
 
 119. Id. Some misdemeanor violations are punishable by fines up to five thousand euro. Id. 
§ 26(2). Other violations can be punishable with fines of up to five-hundred thousand euro. Id. 
 120. Id. § 15(1) (“A prenatal genetic examination may only be conducted for medical purposes 
and to the extent it is targeted at determining certain genetic characteristics of the embryo or foetus 
which, according to the generally accepted status of science and technology, might impair its health 
before or after birth or if treatment of an embryo . . . .”) (emphasis added). The section goes on to say 
that if a fetus’s sex is determined during medical prenatal testing, the parents may find out the results. 
 121. Id. § 1. The GenDG prohibits employers and insurance companies from demanding genetic 
testing of employees and individuals, subject to narrow exceptions. 
 122. Id. 
 123. Id. After having received written information on the contents of the counseling, an individual 
may waive their right to genetic counseling in writing. Id. § 10. Additionally, after counseling, the 
person concerned shall be allowed adequate time for consideration before undergoing the test. Id. 
 124. David Clark, Genetic Exceptionalism and Paternalism Themes in New German Legislation, 
GENOMICS L. REP. (Sept. 2, 2009), available at http://www.genomicslawreport.com/index.php/2009/ 
09/02/genetic-exceptionalism-and-paternalism-themes-in-new-german-legislation/. 
 125. Id. 
 126. GenDG, supra note 116, § 1. 
 127. See Birte Herrfurth-Rödig et al., Predictive Genetic Testing, GER. REF. CTR. FOR ETHICS IN 
THE LIFE SCI. [DRZE] (Nov. 2011) (Ger.), available at http://www.drze.de/in-focus/predictive-genet 
ic-testing. 
Genetic data can touch upon the core areas of an individual’s personality. It can therefore be 
considered to be generally accepted that as far as their own genetic constitution is concerned 
every individual is entitled to a “right to know” as well as a “right not to know.” Both are 
commonly subsumed under the concept of ‘informational self-determination’. Problems arise 
in cases where one person’s right not to know collides with another person’s right to know.  
Id. 
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and employment purposes.128 Concerns about family conflict, stress due to 
positive test results, and the danger of “geneticising the living world,”129 
also contributed to the development of the GenDG.130 The requirement 
that genetic tests be ordered by physicians aims to prevent the 
commercialization of genetic tests, to guarantee appropriate consultation 
prior to genetic testing and the correct interpretation of test results, and to 
protect the results with medical confidentiality requirements.131 The 
GenDG’s mandated involvement of qualified genetics health care 
providers and strict informed consent requirements endeavor to protect 
consumers of genetic testing from both intrinsic and extrinsic ethical, 
psychological, and medical consequences.132  
Despite these admirable goals, many critics believe the German 
legislation’s provisions are misguided and overly paternalistic. It is argued 
that the GenDG is an overly extreme attempt to control German citizens’ 
access to and use of their own genetic information and is based too heavily 
on the idea of “genetic exceptionalism.”133 Others argue that the 
prohibition of employee genetic testing may harm German companies in 
the international market and may be detrimental to insurance 
companies.134 Conversely, some contend that the GenDG has too many 
loopholes and does not go far enough to regulate the genetic testing 
industry.135 
VI. PROACTIVE REGULATION OF DTC TESTING THE U.S.: FOLLOWING 
GERMANY’S LEAD, BUT FORGING A MODERATE PATH 
Considering the questionable validity and utility of DTC genetic tests, 
combined with the potentially serious negative consequences, the United 
States should follow Germany’s example of proactively regulating DTC 
genetic testing. Though the GenDG, taken as a whole, may appear overly 
 
 
 128. Id. 
 129. Id. (available at http://www.drze.de/in-focus/predictive-genetic-testing/ethical-aspects). 
“Geneticising” refers to the reduction of individuals solely to their DNA. Id. 
 130. Id. 
 131. Id. 
 132. Id. 
 133. Clark, supra note 124. Genetic exceptionalism is “the belief that genetic information is 
qualitatively different from other forms of personal or medical information.” Id.; see also Caroline 
Wright, Update on Genetic Non-Discrimination Legislation, PHG FOUNDATION (Aug. 10, 2009), 
http://www.phgfoundation.org/news/4752/. 
 134. See, e.g., Peter Singer, German Genetics Law a Double-Edged Sword, JAPAN TIMES (July 18, 
2009), available at http://www.japantimes.co.jp/text/eo20090718a1.html. 
 135. See New German Law Restricts Genetic Testing, DEUTSCHE WELLE (Apr. 24, 2009), 
http://www.dw-world.de/dw/article/0,,4201588,00.html. 
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paternalistic, specifically when considering the provisions on prenatal 
genetic testing that ban seemingly innocuous testing for fetal sex, the 
provisions related to predictive genetic testing are positive steps in 
regulating DTC testing. The legislation does not hamper genetic 
advances—it still gives people the autonomy to choose predictive genetic 
testing.136 The GenDG merely requires the involvement of a physician to 
ensure fully informed consent and to increase clinical utility of the 
results.137  
The United States should, through a single regulatory body (rather than 
the current fragmented and ineffective regulatory framework), adopt 
regulations similar to the GenDG, though with some notable differences. 
Theoretically, the German approach makes sense, but in effect amounts to 
a total ban of DTC testing.138 Requiring the involvement of physicians 
specializing in genetics would likely be problematic and could severely 
limit an individual’s ability to undergo genome-wide genetic testing.139 
Therefore, rather than adopting a physician-only approach to DTC testing, 
the U.S. should enact pre- and post-test genetic counseling requirements 
by certified professionals and promulgate standardized laboratory and 
methodological requirements to ensure clinical and analytical validity of 
the results.140 Because empirical results are inconclusive as to negative 
effects, the United States should not completely preclude the possibility of 
DTC predictive genetic testing and individual choice to pursue that 
avenue.141 Concerns about individual autonomy and the right to access 
one’s own genetic information persist, so it is doubtful that a complete ban 
of DTC genetic testing would be politically feasible in this country. 
Since 2012, several DTC testing companies have moved to a physician 
only business model, as prescribed in the German legislation and most 
policy recommendations.142 Most physicians, however, lack specialized 
knowledge of genetics and genetic testing.143 Physicians may be ill 
 
 
 136. Id. 
 137. See Herrfurth-Rödig et al., supra note 127. 
 138. See Clark, supra note 124. 
 139. See Heidi Carmen Howard & Pascal Borry, Is There a Doctor in the House? The Presence of 
Physicians in the Direct-to-Consumer Genetic Testing Context, 3 J. COMMUNITY GENETICS 105, 109 
(2012), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312941/. 
 140. See Hogarth et al., supra note 41. 
 141. See, e.g., Cinnamon S. Bloss et al., Direct-to-Consumer Personalized Genetic Testing, 20 
HUM. MOL. GENET. R132 (2011), available at http://hmg.oxfordjournals.org/content/early/2011/08/24/ 
hmg.ddr349.full. 
 142. See Howard & Borry, supra note 139, at 107–08. For a list of DTC companies now 
employing the physician-only model, see GPPC List, supra note 1. 
 143. See Howard & Borry, supra note 139, at 107–08 (pointing out the shortcomings of the 
physician-only approach and the need for further physician education on genetics). For example, the 
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equipped to fully inform patients about genome-wide predictive genetic 
testing.144 Since genetic testing capabilities have progressed rapidly, 
resulting in a shortage of genetics specialists, state boards and medical 
associations should institute continuing physician education programs to 
encourage effective physician involvement in the DTC genetic testing 
process.145 To that end, the National Human Genome Research Institute 
has called for enhanced genetics education in undergraduate and graduate 
medical programs, as well as continuing professional education.146 At this 
point in time, however, requiring the involvement of physicians 
specializing in genetics would be problematic and may severely limit an 
individual’s ability to undergo genome-wide genetic testing.147 Mandating 
physician involvement would likely fail to solve the problems of 
misinformation and uninformed consent, while restricting individual 
access.148 
Balancing the need to combat these problems with the desire for 
personal autonomy, requiring genetic counseling for all DTC tests seems 
to be the best solution. The American Medical Association emphasized the 
importance of genetic counseling in their February 2011 letter to the 
FDA.149 By mandating quality, thorough genetic testing, the U.S. 
regulatory body would continue to allow people to access their genetic 
information, while ensuring that they can fully understand it and cope with 
it.  
 
 
United Kingdom’s National Health Service instituted a program in 2009 to educate physicians on 
genetics. See NHS Starts Pilot Program to Increase Doctors’ Genetics Knowledge, GENOME WEB 
DAILY NEWS (July 30, 2009), http://www.genomeweb.com/nhs-starts-pilot-program-increase-doctors-
genetics-knowledge. 
 144. Howard & Borry, supra note 139, at 109–11. 
 145. Id.; see also AM. ACAD. PEDIATRICS, COMM. ON BIOETHICS, Ethical Issues With Genetic 
Testing in Pediatrics, 107 PEDIATRICS 1451, 1454 (2001), available at http://pediatrics.aappub 
lications.org/content/107/6/1451.full.pdf (“The number of genetic counselors and geneticists is 
insufficient for these professionals to take primary responsibility for managing this technology. As a 
result, primary care physicians will need to expand their knowledge of genetics and the benefits and 
risks of genetic testing.”). 
 146. Improving Providers’ Understanding of Genetic Testing, NAT’L HUMAN GENOME RESOURCE 
INST., http://www.genome.gov/10002396 (last updated Apr. 2006). 
 147. Id. 
 148. Id. 
 149. AMA to FDA: Genetic Testing Should Be Conducted by Qualified Health Professionals, 
AMERICAN MED. ASS’N (Feb. 23, 2011), http://www.ama-assn.org/ama/pub/news/news/genetic-test 
ing-qualified-professionals.page (“Without the benefit of proper medical counseling, patients may 
spend money on direct to consumer genetic tests needlessly or misinterpret the results of the tests, 
causing them to make unnecessary or unhealthy lifestyle changes . . . .”); see also FDA Recognizes 
Role of Genetic Counselors in DTC Testing: A Statement from the National Society of Genetic 
Counselors, NAT’L SOC’Y GENETIC COUNSELORS (Mar. 9, 2011), http://www.nsgc.org/Portals/0/Press 
%20Releases/x110309%20Statement%20on%20FDA%20Panel%20-%20FINALv3%20%20_2_.pdf. 
https://openscholarship.wustl.edu/law_globalstudies/vol12/iss2/9
  
 
 
 
 
2013] REGULATION OF DIRECT-TO-CONSUMER GENETIC TESTING 377 
 
 
 
 
Many call for a transparency-focused approach to the DTC testing 
dilemma, rather than regulating DTC genetic tests through traditional 
channels (like FDA premarket review and approval for medical devices), 
to improve consumers’ awareness of what information is obtainable and 
useful.150 Steps to increase transparency would include making 
participation in the forthcoming National Institutes of Health Genetic 
Testing Registry mandatory rather than voluntary,151 increasing FDA 
transparency efforts, and involving the FTC.152 
Another approach discussed by some scholars is to rely on private tort 
liability to regulate this type of genetic testing.153 It remains to be seen, 
however, if consumers will take action in large enough numbers to 
actually effectuate change.154 Moreover, consumers often may not be able 
to prove the requisite harm for recovery, especially if they are claiming 
only emotional harm.155 Causation would, in many cases, be difficult to 
prove, and many are concerned that relying solely on tort liability could 
 
 
 150. See, e.g., Dan Vorhaus, Transparency First: A Proposal for DTC Genetic Testing 
Regulation, GENOMICS LAW REPORT (May 24, 2010), http://www.genomicslawreport.com/index.php/ 
2010/05/24/transparency-first-a-proposal-for-dtc-genetic-testing-regulation/. 
 151. See Genetic Testing Registry, NAT’L INST. OF HEALTH (NIH), http://www.ncbi.nlm.nih.gov/ 
gtr/ (last updated Oct. 6, 2011). The registry, launched in February 2012, provides access to 
information about genetic tests for inherited genetic variations and is based on voluntary data 
submissions by test developers and manufacturers. Genetic Testing Registry, NIH (Feb. 29, 2012), 
http://oba.od.nih.gov/oba/gtr/GTR_Fact_Sheet_2-28-12.pdf. 
 152. Vorhaus, supra note 150. 
[C]reating greater DTC transparency can be most efficiently accomplished without the 
application of regulations that would be onerous for early-stage DTC companies and their 
investors, restrictive for consumers interested in the broadest access to their genetic 
information and expensive and time-consuming for regulators to enforce. Over the next 6–9 
months, the DTC genetic testing industry and regulators, working together, should take three 
key steps to enhance transparency industry-wide, ensure that customers, regulators and 
healthcare professionals are better able to understand and evaluate the products offered, and 
encourage the DTC industry to grow responsibly without more traditional regulation. 
Id. 
 153. Hogarth et al., supra note 41, at 175 (these product liability claims would generally allege 
that misleading advertising caused financial or physical harm to the consumer); see also Pilar N. 
Ossorio, Product Liability for Predictive Genetic Tests, 41 JURIMETRICS J. 239, 242 (2001) (other 
feasible claims could be breach of express or implied warranty and negligence). 
 154. Ossorio, supra note 153. These cases are subject to the inherent limitations of consumer 
litigation. Consumers may not know or understand their rights, and may have comparably limited 
resources and time to devote to lengthy, complex litigation. Id. 
 155. Hogarth et al., supra note 41, at 175 (“For example, the consumer would need to show that 
the test result led to some harmful action, and that the action was a foreseeable result of the misleading 
information. Emotional harm, such as added anxiety from being told one was at greater likelihood of 
developing a disease, would likely be an insufficient basis for receiving damages in the absence of 
more concrete injury.”). 
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have a chilling effect on the DTC testing industry and predictive genetic 
testing in general.156 
Considering the possible policy approaches to the problem of 
regulating DTC testing, the U.S. should follow Germany’s example and 
favorably consider the goals underlying the GenDG. However, the U.S. 
government should take a more balanced, politically feasible course of 
action. One regulatory body should have the power to mandate thorough, 
satisfactory genetic counseling and stricter, tailored laboratory standards 
and methodologies. 
CONCLUSION 
As genome-wide predictive testing becomes more integrated into the 
health care scheme,157 DTC testing will only become more prominent if 
left unregulated. Some argue that this would be a positive development for 
personalized medicine, prevention, genetic education and awareness, and 
individual autonomy to access one’s own genetic information.158 However, 
considering the many ethical concerns and possible negative consequences 
of predictive DTC genetic testing, such as lack of clinical and analytical 
validity, possible psychological strain, and little clinical utility,159 it is in 
the United States’ interest to limit the unfettered growth of this industry. 
Germany heeded the advice of countless international medical and 
genetics organizations and enacted legislation that protects consumers 
from the possible harms of unregulated predictive genetic testing. The 
United States should follow Germany’s example by requiring satisfactory 
genetic counseling and enacting standardized laboratory procedure 
requirements.160 However, for practical reasons and in order to maintain 
the autonomy that DTC testing gives consumers, the United States should 
stop short of Germany’s physician-only requirement. 
 
 
 156. See Gniady, supra note 47, at 2468–69. 
 157. See Kenneth P. Tercyak et al., Parents’ Attitudes Toward Pediatric Genetic Testing for 
Common Disease Risk, 127 PEDIATRICS 1288, 1289 (2011), available at http://pediatrics.aappubli 
cations.org/content/127/5/e1288.full.pdf. 
 158. See supra Part I, notes 30–41. 
 159. See supra Part II, notes 42–65. 
 160. See Press Release, Coll. Am. Pathologists, CAP Urges Increased Oversight of Direct-to-
Consumer Laboratory Tests Citing Potential Risk to Patients (July 22, 2010), available at http://www. 
cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fs
how&_windowLabel=cntvwrPtlt&cntvwrPtlt{actionForm.contentReference}=media_resources%2Fnews
rel_direct_to_consumer.html&_state=maximized&_pageLabel=cntvwr. The letter stated that “direct-to-
consumer testing is clinical laboratory testing and should be . . . required to meet all applicable 
requirements as defined by CLIA.” Moreover, individuals may need a medical professional to interpret 
the test results and recommend any future steps or treatment. 
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Recent steps taken by the FDA and other regulatory agencies in this 
country, including letters sent by the FDA to several DTC companies161 
and the March 2011 Molecular and Clinical Genetics Panel Meeting, have 
led many to wonder whether the end of the DTC testing industry is 
imminent.162 It remains to be seen what the regulatory result of the FDA’s 
March 2011 meeting might be, if any. But while the risks of DTC genetic 
testing remain possible, the United States would certainly benefit from 
adopting the basic principles of Germany’s protective approach. 
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 161. In Vitro Diagnostics, FDA, http://www.fda.gov/medicaldevices/productsandmedicalprocedur 
es/invitrodiagnostics/default.htm (last updated Feb. 19, 2013). 
 162. See, e.g., Emily Singer, The End for Direct-to-Consumer Genetic Testing?, MIT TECH. REV. 
(Mar. 11, 2011), http://www.technologyreview.com/blog/editors/26499/; see also Bruce Japsen & 
Sandra M. Jones, Walgreens Postpones Carrying Pathway Genomics Genetic Test Kit, L.A. TIMES 
(May 13, 2010), available at http://articles.latimes.com/2010/may/13/business/la-fi-dna-kits-20100513 
(reporting on the FDA’s enforcement letter to Pathway Genomics giving them fifteen days to respond 
to a request for information regarding the product and its lack of FDA approval, and Walgreen’s 
subsequent decision to delay plans to sell the DTC test kits in their drug stores). 
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